Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study is collecting real-world data to evaluate abrocitinib and conventional systemic treatments in moderate-to-severe atopic dermatitis across five European registers over a three-year period.

This review provides a detailed overview of Hashimoto thyroiditis, discussing its epidemiology, risk factors, genetic and environmental contributors, clinical presentations, diagnostic methods, and treatment options, emphasizing the importance of personalized treatment plans due to varied causes and symptoms.

This review examines the clinical presentation of alopecia areata in children and compares it to adult-onset cases, noting that data on pediatric cases is scarce and often varies, with reported onset typically between ages 6 and 12.

This review discusses the role of gut microbiota in autoimmune and immune-mediated dermatological conditions like lupus and psoriasis, but reports no new clinical results; the authors emphasize the need for further study into microbial signatures and treatments.

This meta-analysis found that patients with alopecia areata have significantly higher odds of also having immune-mediated diseases such as atopic dermatitis, autoimmune thyroiditis, inflammatory bowel disease, systemic lupus erythematosus, and vitiligo, suggesting a need for comprehensive screening and interdisciplinary management.

This systematic review and meta-analysis reports a significant familial risk of autoimmune and related conditions among relatives of individuals with Alopecia Areata, highlighting the importance of comprehensive family monitoring and genetic counseling.

Nutrition plays a key role in managing skin disorders, with specific dietary changes helping improve conditions like acne, dermatitis, psoriasis, alopecia, and skin cancer.

This review discusses the complex skin changes associated with obesity and the potential benefits of nutritional interventions for inflammatory skin diseases, without reporting new clinical results.

This study found a reciprocal correlation between depressive disorders and several dermatological autoimmune diseases, such as psoriasis and lupus, suggesting that inflammation may be a shared pathomechanism for these conditions.

This review discusses the psychological and economic impact of alopecia areata in Asia, highlighting significant quality of life reductions and a substantial financial burden on patients without providing new clinical results.

This study found that although the global incidence of alopecia areata has risen since 1990, age-standardized rates have slightly decreased, with significant comorbidity associations varying by region.

In this study, nail changes, particularly pitting, were associated with moderate to severe cases of alopecia areata and a positive family history, highlighting potential genetic factors in the condition.

This review examines the use of monoaminergic antidepressants for inflammatory skin disorders and reports they may reduce dermatological symptoms, suggesting a potential role beyond treating psychiatric conditions.

This review reports a notably higher prevalence and severity of alexithymia among dermatology patients than healthy controls, suggesting its consideration may enhance treatment outcomes and quality of life.

This study reported that in Hispanic/Latinx patients with alopecia areata, rheumatoid arthritis was a common autoimmune comorbidity, and gastroesophageal reflux disease was notably more prevalent than in other populations with alopecia areata.

This research notes that biologics and small molecules are effective for treating nail psoriasis and alopecia areata, albeit with precautions for adverse events, but no clinical trials have been published for their use in treating nail lichen planus and atopic dermatitis.

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

This study found that IBS is positively associated with psoriasis, rosacea, and urticaria, but inversely associated with acne and vitiligo.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

This study found that most dermatologists in the Middle East manage mild to severe alopecia areata primarily with potent topical corticosteroids and identified long-term disease control and improved efficacy as key unmet needs.

Periodontitis may increase the risk of developing alopecia areata.

This study observed that severe forms of alopecia areata were associated with significantly lower vitamin D levels compared to mild forms, suggesting vitamin D as a possible factor in disease severity.

This study analyzed data from 2083 patients with alopecia areata in Europe and found that those with atopic, autoimmune, or psychiatric comorbidities encountered more severe disease and were more likely to require advanced treatments compared to those without comorbid conditions.

This study found that patients with scarring alopecia have higher rates of various systemic conditions, such as vitamin D deficiency and metabolic syndrome, compared to the national averages, and noted a significant association between certain types of scarring alopecia and atherosclerotic cardiovascular disease.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

This research discusses the complex immune pathogenesis of alopecia areata and highlights the success of Jak inhibitors and IL-4Rα antagonists, while IL-17A and PDE4 inhibitors showed limited efficacy; controlled trials are advocated to better understand cytokine involvement.

This review discusses the variety of skin disorders associated with atopic dermatitis, exploring their complex relationships and shared genetic and environmental factors, but reports no new clinical results.

In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.

This case study reports that a 15-year-old male with multiple autoimmune conditions showed significant improvement in skin and gastrointestinal symptoms, along with hair regrowth, after 16 weeks of treatment with the JAK-1 inhibitor upadacitinib, demonstrating its potential in managing complex autoimmune disorders.

This review discusses the diagnosis, treatment, and management of atopic dermatitis in developing countries and identifies significant unmet medical needs, particularly in access to care and effective treatments; it reports no clinical results.